世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

カスタム抗体市場:サービス毎(抗体産生、特性化、免疫付与、断片化)、タイプ毎(モノクローナル、ポリクローナル、組換え)、原料毎(マウス、ラビット)、研究分野毎(がん、免疫)、エンドユーザ毎 - 2023年までの世界市場予測

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年12月US$5,650
シングルユーザライセンス
198 179

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のカスタム抗体市場に関する調査レポートです。

“The global custom antibody market is projected to grow at a CAGR of 8.9%.”

The custom antibody market is expected to reach USD 481 million by 2023 from an estimated USD 313 million in 2018, at a CAGR of 8.9%. Increase in research activities (especially in the life sciences industry), growing industry-academia collaborations, and the expanding antibody therapeutics pipeline are the primary growth drivers for this market. Rapid growth in developing countries across APAC and Latin America and the increasing demand for personalized medicine and protein therapeutics are expected to offer significant growth opportunities for players in this market. However, the need for steep capital investments and long duration of antibody development, along with the increasing focus on antibody alternatives for proteomic studies, are some of the major market challenges.

“Antibody production & purification segment to grow at the highest rate during the forecast period.”

On the basis of services, the custom antibody market is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody production & purification segment is projected to witness the highest growth in the custom antibody services market during the forecast period. Growth in this segment is largely driven by the need for high-quality antibodies for research reproducibility and generating high-quality therapeutics.

“The recombinant antibodies segment is expected to grow at the highest CAGR during the forecast period.”

Based on type, custom antibodies are categorized as monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other custom antibodies. The recombinant antibodies segment is projected to witness the highest growth rate during the forecast period. The increasing development of recombinant antibodies due to their advantages such as batch-to-batch reproducibility, rapid production along with their capability of data reproducibility within research is propelling the growth of this segment during the forecast period.

“APAC is projected to witness the highest growth during the forecast period.”

Even though North America is expected to account for the largest share of the global custom antibody market in 2018, APAC is expected to witness the highest CAGR during the forecast period. The growing Asian scientific base and capability, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, growing awareness about personalized therapeutics, and increasing research activities in the field of mAb-based therapeutics are factors driving the growth of this regional segment.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-48%, Tier 2-34%, and Tier 3-18%
- By Designation: C-level-42%, Director Level-40%, and Others-18%
- By Region: North America-35%, Europe-25%, Asia Pacific-30%, Row - 7%

The prominent players in the global custom antibody market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck Group (Germany), Abcam plc (UK), Cell Signaling Technology, Inc. (US), Agilent Technologies, Inc. (US), GenScript (US), BioLegend, Inc. (US), Rockland Immunochemicals (US), ProMab Biotechnologies (US), Innovagen AB (Sweden), and ProteoGenix (US).

Research Coverage:

The report analyzes the market for various custom antibody services and their adoption pattern. It aims at estimating the market size and future growth potential of the global custom antibody market and different segments such as service, type, source, research area, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global custom antibody market
- Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global custom antibody market
- Market Development: Comprehensive information on the lucrative emerging regions by service, type, source, research area, end user, and region
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global custom antibody market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global custom antibody market



目次

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 STAKEHOLDERS 20
1.6 LIMITATIONS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY RESEARCH 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY RESEARCH 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Break down of primaries 25
2.1.2.3 Key industry insights 26
2.2 MARKET SIZE ESTIMATION 27
2.3 DATA TRIANGULATION APPROACH 29
2.4 MARKET SHARE ESTIMATION 30
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 36
4.1 CUSTOM ANTIBODIES: MARKET OVERVIEW 36
4.2 CUSTOM ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37
4.3 REGIONAL MIX: CUSTOM ANTIBODIES MARKET (2018-2023) 38
4.4 CUSTOM ANTIBODIES MARKET: DEVELOPED VS. DEVELOPING MARKETS,
2018 VS. 2023 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 MARKET DRIVERS 41
5.2.1.1 Increasing research activity and funding 41
5.2.1.2 Quality concerns over catalog antibodies 42
5.2.1.3 Increasing antibody therapeutics and expanding drug pipeline 43
5.2.1.4 Growing industry-academia collaborations 43
5.2.2 MARKET OPPORTUNITIES 44
5.2.2.1 High growth opportunities in emerging countries 44
5.2.2.2 Increasing demand for personalized medicine and protein therapeutics 45
5.2.2.3 Growth in stem cell and CVD research 46
5.2.2.4 Increasing focus on biomarker discovery 47
5.2.3 MARKET CHALLENGES 47
5.2.3.1 Cost- and time-intensive antibody development processes 47
5.2.3.2 Presence of antibody alternatives 48
5.2.4 INDUSTRY TRENDS 49
5.2.4.1 Increasing focus on antibody-drug conjugates (ADCs) 49
5.2.4.2 Development of bispecific antibodies 50

6 CUSTOM ANTIBODY MARKET, BY SERVICE 51
6.1 INTRODUCTION 52
6.2 ANTIBODY DEVELOPMENT 53
6.2.1 ANTIBODY CHARACTERIZATION 54
6.2.1.1 Characterization eliminates antibodies with heterogeneities that may hamper research studies; this is driving market growth 54
6.2.2 ANTIGEN PREPARATION 56
6.2.2.1 Antigen preparation forms one of the most important steps in the antibody production process 56
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 57
6.2.3.1 Specific immunization protocols are followed depending on the antibody required and animal used to generate them 57
6.3 ANTIBODY PRODUCTION & PURIFICATION 58
6.4 ANTIBODY FRAGMENTATION & LABELING 60

7 CUSTOM ANTIBODY MARKET, BY TYPE 61
7.1 INTRODUCTION 62
7.2 MONOCLONAL ANTIBODIES 63
7.2.1 MONOCLONAL ANTIBODIES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
7.3 POLYCLONAL ANTIBODIES 64
7.3.1 POLYCLONAL ABS ARE PREFERRED IN PROTEOMIC RESEARCH FOR DETECTION OF DENATURED PROTEINS 64
7.4 RECOMBINANT ANTIBODIES 66
7.4.1 RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THE GROWTH OF THE RECOMBINANT ANTIBODIES SEGMENT 66
7.5 OTHER CUSTOM ANTIBODIES 67
-
8 CUSTOM ANTIBODY MARKET, BY SOURCE 69
8.1 INTRODUCTION 70
8.2 MICE 70
8.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION 70
8.3 RABBITS 71
8.3.1 ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS 71
8.4 OTHER SOURCES 73

9 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA 74
9.1 INTRODUCTION 75
9.2 ONCOLOGY 76
9.2.1 USE OF ANTIBODIES HAS GROWN CONSIDERABLY IN CANCER RESEARCH 76
9.3 INFECTIOUS DISEASES 77
9.3.1 ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES 77
9.4 IMMUNOLOGY 79
9.4.1 ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY 79
9.5 NEUROBIOLOGY 80
9.5.1 NEUROBIOLOGY FORMS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES 80
9.6 STEM CELLS 81
9.6.1 AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH 81
9.7 CARDIOVASCULAR DISEASES 83
9.7.1 IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES 83
9.8 OTHER RESEARCH AREAS 84

10 CUSTOM ANTIBODY MARKET, BY END USER 85
10.1 INTRODUCTION 86
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 87
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES 87
10.3 ACADEMIC & RESEARCH INSTITUTES 88
10.3.1 INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH 88
10.4 CONTRACT RESEARCH ORGANIZATIONS 90
10.4.1 CROS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES AND OFFER A COST-EFFECTIVE SOLUTION TO DEVELOP DRUGS 90
-
11 CUSTOM ANTIBODY MARKET, BY REGION 92
11.1 INTRODUCTION 93
11.2 NORTH AMERICA 94
11.2.1 US 99
11.2.1.1 Growing research in the field of structure-based drug design and therapeutic mAbs to drive market growth 99
11.2.2 CANADA 102
11.2.2.1 Increasing genomic research to drive the adoption of custom antibodies in the coming years 102
11.3 EUROPE 105
11.3.1 GERMANY 110
11.3.1.1 High investments for the development of ADCs support the growth of the custom antibodies market in Germany 110
11.3.2 UK 113
11.3.2.1 Growing research investments to drive growth in the life science research market, resulting in the growing use of antibodies 113
11.3.3 FRANCE 116
11.3.3.1 Expanding pipeline of therapeutic mAbs along with increasing investments in research are supporting market growth 116
11.3.4 ITALY 119
11.3.4.1 Growing proteomics and genomics research at the academic level to play a key role in market growth in Italy 119
11.3.5 SPAIN 122
11.3.5.1 Increasing focus on the advancement of translational personalized medicine is expected to drive market growth 122
11.3.6 REST OF EUROPE 125
11.4 ASIA PACIFIC 128
11.4.1 JAPAN 133
11.4.1.1 Large number of research initiatives towards the development of various ADCs support market growth in Japan 133
11.4.2 CHINA 136
11.4.2.1 China is one of the fastest-growing markets in the research sector and is expected to dominate the market in the coming years 136
11.4.3 INDIA 139
11.4.3.1 Research for generic mAbs and fusion mAbs as therapeutics is expected to propel the custom antibodies market in the country 139
11.4.4 REST OF ASIA PACIFIC 142
11.5 LATIN AMERICA 146
11.5.1 INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE THE GROWTH OF THE MARKET IN THE REGION 146
11.6 MIDDLE EAST & AFRICA 149
11.6.1 GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON THE AFRICAN MARKET IS DRIVING THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION 149
-
12 COMPETITIVE LANDSCAPE 153
12.1 OVERVIEW 153
12.2 MARKET SHARE ANALYSIS 154
12.3 COMPETITIVE SITUATION AND TRENDS 155
12.3.1 PRODUCT & SERVICES LAUNCHES 155
12.3.2 EXPANSIONS 156
12.3.3 ACQUISITIONS 157
12.3.4 OTHER STRATEGIES 157

13 COMPANY PROFILES 159
(Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 THERMO FISHER SCIENTIFIC INC. 159
13.2 GENSCRIPT 163
13.3 ABCAM PLC 167
13.4 MERCK GROUP 171
13.5 BIO-RAD LABORATORIES, INC. 175
13.6 CELL SIGNALING TECHNOLOGY, INC. 178
13.7 AGILENT TECHNOLOGIES, INC. 180
13.8 BIOLEGEND, INC. 182
13.9 ROCKLAND IMMUNOCHEMICALS INC. 184
13.10 PROMAB BIOTECHNOLOGIES, INC. 186
13.11 PROTEOGENIX 187
13.12 INNOVAGEN AB 189
*Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX 190
14.1 INSIGHTS OF INDUSTRY EXPERTS 190
14.2 DISCUSSION GUIDE 191
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 195
14.4 AVAILABLE CUSTOMIZATIONS 197
14.5 RELATED REPORTS 197
14.6 AUTHOR DETAILS 198

 

LIST OF TABLES

TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS 44
TABLE 2 MARKET OPPORTUNITIES: IMPACT ANALYSIS 47
TABLE 3 MARKET CHALLENGES: IMPACT ANALYSIS 48
TABLE 4 CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 52
TABLE 5 ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 53
TABLE 6 ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 54
TABLE 7 ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 55
TABLE 8 ANTIGEN PREPARATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 56
TABLE 9 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY,  
2016-2023 (USD MILLION) 58
TABLE 10 ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY,  
2016-2023 (USD MILLION) 59
TABLE 11 ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY,  
2016-2023 (USD MILLION) 60
TABLE 12 CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 62
TABLE 13 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 64
TABLE 14 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 65
TABLE 15 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 67
TABLE 16 OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 68
TABLE 17 CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 70
TABLE 18 CUSTOM ANTIBODIES MARKET FOR MICE, BY COUNTRY,
2016-2023 (USD MILLION) 71
TABLE 19 CUSTOM ANTIBODIES MARKET FOR RABBITS, BY COUNTRY,
2016-2023 (USD MILLION) 72
TABLE 20 CUSTOM ANTIBODIES MARKET FOR OTHER SOURCES, BY COUNTRY,  
2016-2023 (USD MILLION) 73
TABLE 21 CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION) 75
TABLE 22 CUSTOM ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY,  
2016-2023 (USD MILLION) 77
TABLE 23 CUSTOM ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  
2016-2023 (USD MILLION) 78
TABLE 24 CUSTOM ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY,  
2016-2023 (USD MILLION) 79
TABLE 25 CUSTOM ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY,  
2016-2023 (USD MILLION) 81
TABLE 26 CUSTOM ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY,  
2016-2023 (USD MILLION) 82
TABLE 27 CUSTOM ANTIBODIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,  2016-2023 (USD MILLION) 83
TABLE 28 CUSTOM ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY,  2016-2023 (USD MILLION) 84
TABLE 29 CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 86
TABLE 30 CUSTOM ANTIBODIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION) 88
TABLE 31 CUSTOM ANTIBODIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION) 90
TABLE 32 CUSTOM ANTIBODIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,  
BY COUNTRY, 2016-2023 (USD MILLION) 91
TABLE 33 CUSTOM ANTIBODIES MARKET, BY REGION, 2016-2023 (USD MILLION) 94
TABLE 34 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY COUNTRY,  
2016-2023 (USD MILLION) 96
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE,  
2016-2023 (USD MILLION) 96
TABLE 36 NORTH AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE,  
2016-2023 (USD MILLION) 96
TABLE 37 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016-2023 (USD MILLION) 97
TABLE 38 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE,  
2016-2023 (USD MILLION) 97
TABLE 39 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 98
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER,  
2016-2023 (USD MILLION) 98
TABLE 41 US: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 99
TABLE 42 US: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 100
TABLE 43 US: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 100
TABLE 44 US: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 100
TABLE 45 US: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 101
TABLE 46 US: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 101
TABLE 47 CANADA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 103
TABLE 48 CANADA: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 103
TABLE 49 CANADA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 103
TABLE 50 CANADA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 104
TABLE 51 CANADA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 104
TABLE 52 CANADA: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 105
TABLE 53 EUROPE: CUSTOM ANTIBODIES MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 107
TABLE 54 EUROPE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 107
TABLE 55 EUROPE: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 107
TABLE 56 EUROPE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 108
TABLE 57 EUROPE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 108
TABLE 58 EUROPE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 109
TABLE 59 EUROPE: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 109
TABLE 60 GERMANY: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016-2023 (USD MILLION) 110
TABLE 61 GERMANY: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 111
TABLE 62 GERMANY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 111
TABLE 63 GERMANY: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016-2023 (USD MILLION) 111
TABLE 64 GERMANY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 112
TABLE 65 GERMANY: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 112
TABLE 66 UK: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 113
TABLE 67 UK: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 114
TABLE 68 UK: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 114
TABLE 69 UK: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 115
TABLE 70 UK: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 115
TABLE 71 UK: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 115
TABLE 72 FRANCE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 117
TABLE 73 FRANCE: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 117
TABLE 74 FRANCE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 117
TABLE 75 FRANCE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 118
TABLE 76 FRANCE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 118
TABLE 77 FRANCE: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 119
TABLE 78 ITALY: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 120
TABLE 79 ITALY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 120
TABLE 80 ITALY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 120
TABLE 81 ITALY: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 121
TABLE 82 ITALY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 121
TABLE 83 ITALY: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 122
TABLE 84 SPAIN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 123
TABLE 85 SPAIN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 123
TABLE 86 SPAIN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 123
TABLE 87 SPAIN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 124
TABLE 88 SPAIN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 124
TABLE 89 SPAIN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 125
TABLE 90 ROE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 126
TABLE 91 ROE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 126
TABLE 92 ROE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 127
TABLE 93 ROE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 127
TABLE 94 ROE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 127
TABLE 95 ROE: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 128
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 130
TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016-2023 (USD MILLION) 130
TABLE 98 ASIA PACIFIC: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 130
TABLE 99 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016-2023 (USD MILLION) 131
TABLE 100 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016-2023 (USD MILLION) 131
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 132
TABLE 102 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 132
TABLE 103 JAPAN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 134
TABLE 104 JAPAN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 134
TABLE 105 JAPAN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 134
TABLE 106 JAPAN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 135
TABLE 107 JAPAN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 135
TABLE 108 JAPAN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 136
TABLE 109 CHINA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 137
TABLE 110 CHINA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 137
TABLE 111 CHINA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 138
TABLE 112 CHINA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 138
TABLE 113 CHINA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 138
TABLE 114 CHINA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 139
TABLE 115 INDIA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 140
TABLE 116 INDIA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION) 140
TABLE 117 INDIA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 141
TABLE 118 INDIA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 141
TABLE 119 INDIA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016-2023 (USD MILLION) 142
TABLE 120 INDIA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION) 142
TABLE 121 ROAPAC: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION) 143
TABLE 122 ROAPAC: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 144
TABLE 123 ROAPAC: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION) 144
TABLE 124 ROAPAC: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION) 144
TABLE 125 ROAPAC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 145
TABLE 126 ROAPAC: CUSTOM ANTIBODIES MARKET, BY END USER,
2016-2023 (USD MILLION) 145
TABLE 127 LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016-2023 (USD MILLION) 146
TABLE 128 LATIN AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE,  
2016-2023 (USD MILLION) 147
TABLE 129 LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016-2023 (USD MILLION) 147
TABLE 130 LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016-2023 (USD MILLION) 148
TABLE 131 LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2016-2023 (USD MILLION) 148
TABLE 132 LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER,  
2016-2023 (USD MILLION) 149
TABLE 133 MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SERVICE,  
2016-2023 (USD MILLION) 150
TABLE 134 MIDDLE EAST & AFRICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE,  
2016-2023 (USD MILLION) 150
TABLE 135 MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY TYPE,  
2016-2023 (USD MILLION) 151
TABLE 136 MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SOURCE,  
2016-2023 (USD MILLION) 151
TABLE 137 MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  2016-2023 (USD MILLION) 152
TABLE 138 MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY END USER,  
2016-2023 (USD MILLION) 152
TABLE 139 CUSTOM ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2017 154
TABLE 140 PRODUCT AND SERVICE LAUNCHES, 2015-2018 156
TABLE 141 EXPANSIONS, 2015-2018 156
TABLE 142 ACQUISITIONS, 2015-2018 157
TABLE 143 OTHER STRATEGIES, 2015-2018 158

 

LIST OF FIGURES

FIGURE 1 CUSTOM ANTIBODY MARKET 19
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION 25
FIGURE 4 BOTTOM-UP APPROACH 27
FIGURE 5 TOP-DOWN APPROACH 28
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
FIGURE 7 CUSTOM ANTIBODIES MARKET, BY SERVICE, 2018 VS. 2023 (USD MILLION) 31
FIGURE 8 CUSTOM ANTIBODIES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 32
FIGURE 9 CUSTOM ANTIBODIES MARKET, BY SOURCE, 2018 VS. 2023 (USD MILLION) 33
FIGURE 10 CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  
2018 VS. 2023 (USD MILLION) 33
FIGURE 11 CUSTOM ANTIBODIES MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 34
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE CUSTOM ANTIBODIES MARKET 35
FIGURE 13 QUALITY CONCERNS OVER CATALOG ANTIBODIES & THE EXPANDING AB THERAPEUTICS PIPELINE TO DRIVE MARKET GROWTH 36
FIGURE 14 US DOMINATED THE CUSTOM ANTIBODIES MARKET IN 2017 37
FIGURE 15 APAC TO REGISTER THE HIGHEST GROWTH RATE DURING
THE FORECAST PERIOD (2018-2023) 38
FIGURE 16 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2018 & 2023 39
FIGURE 17 CUSTOM ANTIBODIES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 40
FIGURE 18 R&D INVESTMENTS, BY COUNTRY (USD BILLION) 42
FIGURE 19 NUMBER OF THERAPEUTIC ANTIBODIES APPROVED FOR MARKET RELEASE (2011-2017) 43
FIGURE 20 PERSONALIZED MEDICINE PRODUCTS, 2008-2016 45
FIGURE 21 INCREASING FOCUS ON ADCS & THE DEVELOPMENT OF BISPECIFIC ANTIBODIES ARE THE KEY MARKET TRENDS 49
FIGURE 22 ANTIBODY DEVELOPMENT SERVICES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD 52
FIGURE 23 RECOMBINANT ANTIBODIES SEGMENT IS EXPECTED TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 62
FIGURE 24 ONCOLOGY TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD 75
FIGURE 25 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD 86
FIGURE 26 CUSTOM ANTIBODIES MARKET: GEOGRAPHIC SNAPSHOT (2017) 93
FIGURE 27 NORTH AMERICA: CUSTOM ANTIBODIES MARKET SNAPSHOT 95
FIGURE 28 EUROPE: CUSTOM ANTIBODIES MARKET SNAPSHOT 106
FIGURE 29 ASIA PACIFIC: CUSTOM ANTIBODIES MARKET SNAPSHOT 129
FIGURE 30 EXPANSIONS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018 153
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 159
FIGURE 32 GENSCRIPT: COMPANY SNAPSHOT 163
FIGURE 33 ABCAM PLC: COMPANY SNAPSHOT 167
FIGURE 34 MERCK GROUP: COMPANY SNAPSHOT 171
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 175
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 180

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る